Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 25 2025
0mins
Should l Buy ?
Source: Newsfilter
Company Merger and Trading: Inmagene Biopharmaceuticals has merged with Ikena Oncology to form ImageneBio, Inc., which will begin trading on Nasdaq under the ticker symbol "IMA" starting July 28, 2025.
Clinical Trials and Product Development: The new company will continue the Phase 2b clinical trial of its lead product, IMG-007, a monoclonal antibody for treating moderate-to-severe atopic dermatitis, with topline results expected in Q4 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
